| Year |
Citation |
Score |
| 2020 |
Rankin A, Johnson A, Roos A, Kannan G, Knipstein J, Britt N, Rosenzweig M, Haberberger J, Pavlick DC, Severson E, Vergilio JA, Squillace R, Erlich RL, Sathyan P, Cramer S, et al. Targetable BRAF and RAF1 alterations in advanced pediatric cancers. The Oncologist. PMID 32918774 DOI: 10.1002/Onco.13519 |
0.366 |
|
| 2020 |
Lin DI, Hemmerich A, Edgerly C, Duncan D, Severson EA, Huang RSP, Ramkissoon SH, Connor YD, Shea M, Hecht JL, Ali SM, Vergilio JA, Ross JS, Elvin JA. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. Gynecologic Oncology. PMID 32156473 DOI: 10.1016/J.Ygyno.2020.02.024 |
0.373 |
|
| 2020 |
Woolbright WC, Wong V, Severson E, Kuo DJ. The Application of Next-generation Sequencing Tumor Molecular Profiling in the Diagnosis and Management of a Case of Acute Myelogenous Leukemia With MLL-PTD (Partial Tandem Duplication) in a Pediatric Heart Transplant Recipient. Journal of Pediatric Hematology/Oncology. PMID 32134843 DOI: 10.1097/Mph.0000000000001772 |
0.318 |
|
| 2020 |
Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, et al. Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. The Oncologist. 25: e198-e202. PMID 32043779 DOI: 10.1634/Theoncologist.2019-0603 |
0.344 |
|
| 2020 |
Bratslavsky G, Necchi A, Grivas P, Shapiro O, Jacob J, Elvin JA, Vergilio J, Killian K, Lin DI, Williams E, Ramkissoon SH, Severson EA, Hemmerich A, Schrock AB, Chung J, et al. Metastatic renal cell carcinoma (mRCC) in young patients: A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 38: 727-727. DOI: 10.1200/Jco.2020.38.6_Suppl.727 |
0.365 |
|
| 2020 |
Yakirevich E, Perrino C, Necchi A, Grivas P, Bratslavsky G, Shapiro O, Jacob J, Sokol E, Vergilio J, Killian K, Lin DI, Ramkissoon SH, Severson EA, Chung J, Alexander BM, et al. NF2 mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 38: 726-726. DOI: 10.1200/Jco.2020.38.6_Suppl.726 |
0.364 |
|
| 2020 |
Grivas P, Necchi A, Bratslavsky G, Shapiro O, Jacob J, Elvin JA, Vergilio J, Killian K, Williams E, Ramkissoon SH, Severson EA, Hemmerich A, Schrock AB, Chung J, McGregor K, et al. The emerging target KRAS G12C in genitourinary malignancies. Journal of Clinical Oncology. 38: 434-434. DOI: 10.1200/Jco.2020.38.6_Suppl.434 |
0.355 |
|
| 2020 |
Jacob J, Shapiro O, Necchi A, Grivas P, Sokol E, Vergilio J, Killian K, Lin DI, Williams E, Ramkissoon SH, Severson EA, Hemmerich A, Chung J, Alexander BM, McGregor K, et al. Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa). Journal of Clinical Oncology. 38: 5087-5087. DOI: 10.1200/Jco.2020.38.6_Suppl.426 |
0.349 |
|
| 2020 |
Necchi A, Grivas P, Bratslavsky G, Shapiro O, Jacob J, Sokol E, Vergilio J, Killian K, Lin DI, Ramkissoon SH, Severson EA, Hemmerich A, Chung J, Alexander BM, Reddy P, et al. Comprehensive genomic profiling (CGP) in post-systemic treatment (Post) metastatic sites (MET) and pretreatment (Pre) primary tumors (PT) of metastatic prostate cancer (mPC). Journal of Clinical Oncology. 38: 175-175. DOI: 10.1200/Jco.2020.38.6_Suppl.175 |
0.3 |
|
| 2020 |
Ross JS, Sokol E, Vergilio J, Killian K, Lin DI, Williams E, Danziger N, Ramkissoon SH, Severson EA, Hemmerich A, Edgerly CI, Huang R, Ali SM, Madison R, Alexander BM, et al. Primary versus metastatic intrahepatic cholangiocarcinoma: A comparative comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 38: 578-578. DOI: 10.1200/Jco.2020.38.4_Suppl.578 |
0.337 |
|
| 2020 |
Necchi A, Grivas P, Bratslavsky G, Shapiro O, Jacob JM, Sokol E, Killian JK, Lin DI, Ramkissoon SH, Severson EA, Huang R, Alexander BM, Venstrom J, Reddy VP, McGregor K, et al. Contrasting genomic profiles in post-systemic treatment metastatic sites (MET), pretreatment primary tumors (PT), and liquid biopsies (LB) of clinically advanced prostate cancer (PC). Journal of Clinical Oncology. 38: 5534-5534. DOI: 10.1200/Jco.2020.38.15_Suppl.5534 |
0.341 |
|
| 2020 |
Bratslavsky G, Necchi A, Grivas P, Shapiro O, Jacob JM, Elvin JA, Vergilio J, Killian JK, Williams EA, Ramkissoon SH, Severson EA, Hemmerich A, Schrock AB, McGregor K, Reddy VP, et al. Clinically advanced renal cell carcinoma (RCC) and renal sarcoma (RSC) in young patients: A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 38: 5066-5066. DOI: 10.1200/Jco.2020.38.15_Suppl.5066 |
0.37 |
|
| 2020 |
Ross JS, Sokol E, Pavlick D, Vergilio J, Killian JK, Lin DI, Williams EA, Danziger N, Ramkissoon SH, Severson EA, Hemmerich A, Edgerly CI, Huang R, Madison R, Schrock AB, et al. Primary tumor (p-bx) versus metastatic tumor (m-bx) tissue versus liquid biopsy (lb) in intrahepatic cholangiocarcinoma (IHCC): A comparative comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 38: 4579-4579. DOI: 10.1200/Jco.2020.38.15_Suppl.4579 |
0.377 |
|
| 2020 |
Killian JK, Wright C, Chan L, Danziger N, Elvin JA, Vergilio J, Lin DI, Williams EA, Ramkissoon SH, Severson EA, Hemmerich A, Duncan D, Edgerly CI, Tse JY, McGregor K, et al. Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial. Journal of Clinical Oncology. 38: 3622-3622. DOI: 10.1200/Jco.2020.38.15_Suppl.3622 |
0.333 |
|
| 2020 |
Sokol E, Danziger N, Pavlick D, Elvin JA, Vergilio J, Killian JK, Lin DI, Ramkissoon SH, Severson EA, Hemmerich A, Duncan D, Edgerly CI, Huang R, Chung J, Reddy VP, et al. Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 38: 3558-3558. DOI: 10.1200/Jco.2020.38.15_Suppl.3558 |
0.327 |
|
| 2020 |
Necchi A, Grivas P, Bratslavsky G, Killian JK, Lin DI, Williams EA, Ramkissoon SH, Severson EA, Alexander BM, Venstrom J, Reddy VP, McGregor K, Elvin JA, Schrock AB, Pavlick D, et al. Primary adult retroperitoneal sarcoma (RS): Comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 38: 11541-11541. DOI: 10.1200/Jco.2020.38.15_Suppl.11541 |
0.337 |
|
| 2020 |
Killian JK, Yang XR, Danziger N, Elvin JA, Vergilio J, Lin DI, Williams EA, Ramkissoon SH, Severson EA, Hemmerich A, Duncan D, Edgerly CI, Huang R, Hiemenz M, Reddy VP, et al. Differential genomic landscape of clinically advanced/metastatic chordomas (mChor) based on primary tumor site. Journal of Clinical Oncology. 38: 11521-11521. DOI: 10.1200/Jco.2020.38.15_Suppl.11521 |
0.388 |
|
| 2020 |
McGregor K, Sokol E, Danziger N, Pavlick D, Elvin JA, Vergilio J, Killian JK, Lin DI, Williams EA, Ramkissoon SH, Severson EA, Hemmerich A, Duncan D, Huang R, Chung J, et al. Acquired RB1 mutations in estrogen receptor-positive (ER+) clinically advanced and metastatic breast cancer (MBC). Journal of Clinical Oncology. 38: 1053-1053. DOI: 10.1200/Jco.2020.38.15_Suppl.1053 |
0.302 |
|
| 2020 |
Necchi A, Grivas P, Bratslavsky G, Shapiro O, Jacob J, Sokol E, Vergilio JA, Killian K, Lin D, Williams E, Haberberger J, Tse J, Ramikssoon S, Severson E, Hemmerich A, et al. Mp09-02 Contrasting Genomic Profiles In Post-Systemic Treatment Metastatic Sites (Met) And Pre-Treatment Primary Tumors (Pt) Of Clinically Advanced Prostate Cancer (Pc) The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000829.02 |
0.336 |
|
| 2019 |
Cassidy DP, Chapman JR, Lopez R, White K, Fan YS, Casas C, Severson EA, Vega F. Comparison Between Integrated Genomic DNA/RNA Profiling and Fluorescence In Situ Hybridization in the Detection of MYC, BCL-2, and BCL-6 Gene Rearrangements in Large B-Cell Lymphomas. American Journal of Clinical Pathology. PMID 31872861 DOI: 10.1093/Ajcp/Aqz172 |
0.304 |
|
| 2019 |
Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 10: 4018-4025. PMID 31258846 DOI: 10.18632/Oncotarget.26998 |
0.373 |
|
| 2019 |
Lin DI, Allen JM, Hecht JL, Killian JK, Ngo NT, Edgerly C, Severson EA, Ali SM, Erlich RL, Ramkissoon SH, Vergilio JA, Ross JS, Elvin JA. SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 31190001 DOI: 10.1038/S41379-019-0303-Z |
0.412 |
|
| 2019 |
Necchi A, Bratslavsky G, Shapiro O, Elvin JA, Vergilio JA, Killian JK, Ngo N, Ramkissoon S, Severson E, Hemmerich AC, Ali SM, Chung JH, Reddy P, Miller VA, Schrock AB, et al. Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. European Urology Focus. PMID 31147264 DOI: 10.1016/J.Euf.2019.05.012 |
0.326 |
|
| 2019 |
Maxwell K, Severson EA, Montesion M, Marino I, Anhorn R, Sawchyn B. CGE19-064: Patient Access to Comprehensive Genomic Profiling for Hematologic Malignancies: Analysis of the Payer Coverage Landscape and Results of Testing in 3,600 Patients Journal of the National Comprehensive Cancer Network. 17. DOI: 10.6004/Jnccn.2018.7255 |
0.311 |
|
| 2019 |
Necchi A, Bratslavsky G, Pinkhasov R, Shapiro O, Elvin JA, Vergilio J, Killian JK, Nho NT, Ramkissoon S, Severson EA, Hemmerich A, Ali SM, Chung J, Reddy VP, Miller VA, et al. Genomic features of metastatic testicular sex cord stromal tumors. Journal of Clinical Oncology. 37: 532-532. DOI: 10.1200/Jco.2019.37.7_Suppl.532 |
0.356 |
|
| 2019 |
Bratslavsky G, Necchi A, Shapiro O, Jacob J, Alexander BM, Elvin JA, Vergilio J, Killian JK, Nho NT, Ramkissoon S, Severson EA, Hemmerich A, Ali SM, Chung J, Reddy VP, et al. Malignant pheochromocytoma: A comprehensive genomic profiling study. Journal of Clinical Oncology. 37: 508-508. DOI: 10.1200/Jco.2019.37.7_Suppl.508 |
0.364 |
|
| 2019 |
Ross JS, Elvin JA, Vergilio J, Killian JK, Ngo N, Ramkissoon S, Severson EA, Hemmerich A, Duncan D, Ali SM, Chung J, Reddy P, Miller VA, Madison R, Schrock AB, et al. Anal melanoma: A comparative comprehensive genomic profiling study. Journal of Clinical Oncology. 37: 9566-9566. DOI: 10.1200/Jco.2019.37.4_Suppl.551 |
0.373 |
|
| 2019 |
Tse J, Elvin JA, Vergilio J, Killian JK, Ngo N, Lin DI, Ramkissoon S, Severson EA, Hemmerich A, Pavlick D, Ali SM, Schrock AB, Chung J, Reddy P, McGregor K, et al. Extra-mammary Paget’s disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 37: 9591-9591. DOI: 10.1200/Jco.2019.37.15_Suppl.9591 |
0.365 |
|
| 2019 |
Bratslavsky G, Jacob J, Shapiro O, Liu N, Ferry EK, Elvin JA, Vergilio J, Killian JK, Ngo N, Ramkissoon S, Severson EA, Hemmerich A, Ali SM, Chung J, Schrock AB, et al. Ductal (PDC), acinar (PAC) and neuroendocrine (PNC) carcinomas of the prostate: A comparative comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 37: 5064-5064. DOI: 10.1200/Jco.2019.37.15_Suppl.5064 |
0.345 |
|
| 2019 |
Jacob J, Bratslavsky G, Shapiro O, Liu N, Elvin JA, Vergilio J, Killian JK, Ngo N, Lin DI, Ramkissoon S, Severson EA, Ali SM, Chung J, Schrock AB, Reddy P, et al. Metastatic penile (mPSCC), uterine cervical (mCSCC), and skin (mSSCC) squamous cell carcinomas: A comparative genomic profiling (CGP) study. Journal of Clinical Oncology. 37: 4585-4585. DOI: 10.1200/Jco.2019.37.15_Suppl.4585 |
0.364 |
|
| 2019 |
Bratslavsky G, Necchi A, Shapiro O, Jacob J, Elvin JA, Vergilio J, Killian JK, Ngo N, Ramkissoon S, Severson EA, Hemmerich A, Ali SM, Chung J, Reddy P, Miller VA, et al. Malignant pheochromocytoma (MP): A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 37: 4584-4584. DOI: 10.1200/Jco.2019.37.15_Suppl.4584 |
0.363 |
|
| 2019 |
Jacob J, Bratslavsky G, Shapiro O, Liu N, Ferry EK, Basnet A, Elvin JA, Vergilio J, Killian JK, Ramkissoon S, Severson EA, Ali SM, Chung J, Schrock AB, Reddy P, et al. Adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder: A Comprehensive Genomic Profiling (CGP) Study. Journal of Clinical Oncology. 37: 4533-4533. DOI: 10.1200/Jco.2019.37.15_Suppl.4533 |
0.358 |
|
| 2019 |
Madison R, Sokol E, Schrock AB, Johnson A, Pavlick D, Elvin JA, Vergilio J, Ngo N, Killian JK, Lin DI, Ramkissoon S, Severson EA, Hemmerich A, Duncan D, Ali SM, et al. FGFR2: A pan-genomic target. Journal of Clinical Oncology. 37: 3099-3099. DOI: 10.1200/Jco.2019.37.15_Suppl.3099 |
0.376 |
|
| 2019 |
Ross JS, Sokol E, Albacker LA, Frampton GM, Pavlick D, Elvin JA, Vergilio J, Killian JK, Ngo N, Lin DI, Ramkissoon S, Severson EA, Ali SM, Schrock AB, Chung J, et al. Immunotherapy predictive biomarkers in metastatic breast cancer (MBC). Journal of Clinical Oncology. 37: 1023-1023. DOI: 10.1200/Jco.2019.37.15_Suppl.1023 |
0.308 |
|
| 2019 |
Massoth LR, Hung YP, Ferry JA, Hasserjian RP, Louissaint A, Montesion M, Sokol ES, Pavlick DC, Shah N, Danziger N, Killian JK, Severson EA, Duncan D, Elvin JA, Miller VA, et al. Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations Blood. 134: 2541-2541. DOI: 10.1182/Blood-2019-123729 |
0.371 |
|
| 2019 |
Elvin J, Vergilio J, Killian J, Ramkissoon S, Severson E, Daniel S, Hammerich A, Sokol E, Frampton G, Chung J, Trabucco S, Ali S, Reddy P, Schrock A, Miller V, et al. Abstract P3-06-18: Comprehensive genomic profiling of carcinosarcomas of the breast Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P3-06-18 |
0.405 |
|
| 2019 |
Daneshvar M, Necchi A, Shapiro O, Jacob JM, Alexander BM, Elvin JA, Vergilio J, Killian JK, Nho NT, Ramkissoon S, Severson EA, Hemmerich A, Ali SM, Chung J, Reddy VP, et al. Mp69-09 Malignant Pheochromocytoma: A Comprehensive Genomic Profiling Study The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557042.93745.99 |
0.354 |
|
| 2019 |
Killian JK, Pavlick DC, Sokol ES, Montesion M, Jin DX, Kaplan B, Lin D, Vergilio J-, Elvin JA, Ngo N, Severson E, Ramkissoon S, Duncan D, Edgerly C, Hemmerich A, et al. Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz269.056 |
0.346 |
|
| 2019 |
Graziano SL, Lin D, Elvin JA, Vergilio J-, Killian JK, Ngo N, Ramkissoon S, Severson E, Hemmerich A, Duncan D, Edgerly C, Ali SM, Schrock AB, Chung J, Sokol ES, et al. SMARCA4 deficient non-small cell lung cancer (NSCLC): A comprehensive genomic profiling (CGP) study Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz260.105 |
0.333 |
|
| 2019 |
Ou SI, Sokol ES, Trabucco SE, Jin DX, Frampton GM, Graziano SL, Elvin JA, Vergilio J-, Killian JK, Ngo N, Lin D, Ramkissoon S, Severson E, Ali SM, Schrock AB, et al. NTRK1-3 genomic fusions in non-small cell lung cancer (NSCLC) determined by comprehensive genomic profiling Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz260.071 |
0.35 |
|
| 2019 |
Bratslavsky G, Sokol ES, Necchi A, Shapiro O, Jacob J, Liu N, Elvin JA, Vergilio J-, Killian JK, Ngo N, Lin D, Ramkissoon S, Severson E, Ali SM, Schrock AB, et al. Malignant non-adrenal paraganglioma (mPara) and adrenal pheochromocytoma (mPheo) a comparative comprehensive genomic profiling (CGP) study Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz245 |
0.346 |
|
| 2018 |
Jacob JM, Ferry EK, Gay LM, Elvin JA, Vergilio J, Ramkissoon S, Severson E, Necchi A, Killian JK, Ali SM, Schrock AB, Liu NW, Chung J, Miller VA, Stephens PJ, et al. Comparative Genomic Profiling of Refractory/Metastatic Penile and non-Penile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. The Journal of Urology. PMID 30291913 DOI: 10.1016/J.Juro.2018.09.056 |
0.363 |
|
| 2018 |
Severson EA, Vergilio JA, Gay LM, Daniel S, Hemmerich AC, Elvin JA, Britt N, Nahas M, Cohen MB, Brown C, Sathyan P, Rankin A, Miller V, Ross JS, Ramkissoon SH. Genomic Landscape of Adult and Pediatric -Like B-Lymphoblastic Leukemia Using Parallel DNA and RNA Sequencing. The Oncologist. PMID 30181314 DOI: 10.1634/Theoncologist.2018-0272 |
0.311 |
|
| 2018 |
Necchi A, Bratslavsky G, Corona RJ, Chung JH, Millis SZ, Elvin JA, Vergilio JA, Suh J, Ramkissoon S, Severson E, Daniel S, Killian JK, Ali SM, Schrock AB, Reddy P, et al. Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. European Urology Focus. PMID 30025711 DOI: 10.1016/J.Euf.2018.07.013 |
0.36 |
|
| 2018 |
Ramkissoon LA, Britt N, Guevara A, Whitt E, Severson E, Sathyan P, Gay L, Elvin J, Ross JS, Brown C, Stogner-Underwood K, Mott R, Kram D, Strowd R, Lesser GJ, et al. Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas. Current Treatment Options in Oncology. 19: 41. PMID 29931654 DOI: 10.1007/S11864-018-0559-4 |
0.383 |
|
| 2018 |
Tarlock K, Zhong S, He Y, Ries R, Severson E, Bailey M, Morley S, Balasubramanian S, Erlich R, Lipson D, Otto GA, Vergillo JA, Kolb EA, Ross JS, Mughal T, et al. Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. Oncotarget. 9: 26417-26430. PMID 29899868 DOI: 10.18632/Oncotarget.25443 |
0.31 |
|
| 2018 |
Severson EA, Riedlinger GM, Connelly CF, Vergilio JA, Goldfinger M, Ramkissoon S, Frampton GM, Ross JS, Fratella-Calabrese A, Gay L, Ali S, Miller V, Elvin J, Hadigol M, Hirshfield KM, et al. Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood. PMID 29678827 DOI: 10.1182/Blood-2018-03-840629 |
0.315 |
|
| 2018 |
Jacob JM, Ferry EK, Shapiro O, Millis SZ, Chung J, Elvin JA, Vergilio J, Ramkissoon S, Suh J, Severson EA, Daniel S, Ali SM, Schrock AB, Miller VA, Stephens PJ, et al. Refractory testicular pure seminoma (PS) and non-seminomatous(NS) germ cell tumors (GCT): A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 36: 565-565. DOI: 10.1200/Jco.2018.36.6_Suppl.565 |
0.385 |
|
| 2018 |
Bratslavsky G, Fisher HAG, Byler T, Jacob JM, Chung J, Elvin JA, Vergilio J, Ramkissoon S, Suh J, Severson EA, Daniel S, Ali SM, Schrock AB, Miller VA, Stephens PJ, et al. Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TMPRSS2:ERG wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC). Journal of Clinical Oncology. 36: 348-348. DOI: 10.1200/Jco.2018.36.6_Suppl.348 |
0.343 |
|
| 2018 |
Corona RJ, Ross JS, Elvin JA, Vergilio J, Suh J, Ramkissoon SH, Daniel S, Killian JK, Severson EA, Chung J, Ali SM, Schrock AB, Miller VA, Bratslavsky G. Primary sarcomas of the urinary bladder: A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E16530 |
0.334 |
|
| 2018 |
Corona RJ, Ramkissoon SH, Elvin JA, Suh J, Vergilio J, Severson EA, Daniel S, Killian JK, Ali SM, Schrock AB, Chung J, Lesser GJ, Aridgides PD, Miller VA, Ross JS. Choroid plexus tumors of the central nervous system: Searching for therapy targets with comprehensive genomic profiling. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E14084 |
0.389 |
|
| 2018 |
Girard N, Elvin JA, Vergilio J, Suh J, Ramkissoon S, Daniel S, Severson EA, Killian K, Ali SM, Schrock AB, Chung J, Carlson JA, Jones D, Miller VA, Mihm MC, et al. Comprehensive genomic profiling of metastatic cutaneous adnexal carcinomas to reveal multiple routes to targeted and immunotherapies. Journal of Clinical Oncology. 36: 9587-9587. DOI: 10.1200/Jco.2018.36.15_Suppl.9587 |
0.346 |
|
| 2018 |
Ross JS, Sokol E, Elvin JA, Vergilio J, Suh J, Ramkissoon SH, Daniel S, Severson EA, Killian JK, Ali SM, Schrock AB, Chung J, Frampton GM, Albacker LA, Corona RJ, et al. PBRM1 genomic alterations in mesothelioma: Potential predictor of immunotherapy efficacy. Journal of Clinical Oncology. 36: 8562-8562. DOI: 10.1200/Jco.2018.36.15_Suppl.8562 |
0.357 |
|
| 2018 |
Kotula L, Bratslavsky G, Fisher HAG, Byler T, Corona RJ, Jacob J, Basnet A, Chung J, Elvin JA, Vergilio J, Suh J, Ramkissoon SH, Daniel S, Severson EA, Schrock AB, et al. Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC). Journal of Clinical Oncology. 36: 5061-5061. DOI: 10.1200/Jco.2018.36.15_Suppl.5061 |
0.321 |
|
| 2018 |
Necchi A, Bratslavsky G, Corona RJ, Chung J, Millis SZ, Elvin JA, Vergilio J, Suh J, Ramkissoon S, Severson EA, Daniel S, Killian JK, Ali SM, Schrock AB, Miller VA, et al. Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT). Journal of Clinical Oncology. 36: 4555-4555. DOI: 10.1200/Jco.2018.36.15_Suppl.4555 |
0.325 |
|
| 2018 |
Ross JS, Ferry EK, Jacob J, Shapiro O, Hoffman-Censits JH, Millis SZ, Elvin JA, Chung J, Vergilio J, Suh J, Ramkissoon SH, Severson EA, Daniel S, Killian JK, Ali SM, et al. FGFR3 Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study. Journal of Clinical Oncology. 36: 4531-4531. DOI: 10.1200/Jco.2018.36.15_Suppl.4531 |
0.381 |
|
| 2018 |
Ali SM, Elvin JA, Vergilio J, Ramkissoon SH, Suh J, Severson EA, Daniel S, Killian JK, Schrock AB, Chung J, Frampton GM, Fabrizio D, Albacker LA, Miller VA, Corona RJ, et al. MSI-high and MSI-stable colorectal carcinomas (CRC): A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 36: 3574-3574. DOI: 10.1200/Jco.2018.36.15_Suppl.3574 |
0.324 |
|
| 2018 |
Fabrizio D, Frampton GM, Albacker LA, Sokol E, Elvin JA, Vergilio J, Suh J, Ramkissoon SH, Severson EA, Daniel S, Ali SM, Chung J, Schrock AB, Miller VA, Pu JJ, et al. PD-L1 genomic alterations (GA) in solid tumors and hematologic malignancies: A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 36: 12092-12092. DOI: 10.1200/Jco.2018.36.15_Suppl.12092 |
0.301 |
|
| 2018 |
Bratslavsky G, Gay LM, Sokol E, Elvin JA, Vergilio J, Suh J, Ramkissoon SH, Daniel S, Severson EA, Killian JK, Ali SM, Chung J, Schrock AB, Frampton GM, Fabrizio D, et al. PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment. Journal of Clinical Oncology. 36: 12091-12091. DOI: 10.1200/Jco.2018.36.15_Suppl.12091 |
0.393 |
|
| 2018 |
Beaucaire-Danel S, Girard N, Elvin JA, Suh J, Vergilio J, Ramkissoon SH, Severson EA, Daniel S, Killian JK, Ali SM, Schrock AB, Chung J, Corona RJ, Miller VA, Ross JS. Primary pulmonary sarcomas (PSRC): A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 36: 11553-11553. DOI: 10.1200/Jco.2018.36.15_Suppl.11553 |
0.325 |
|
| 2018 |
Ross J, Chung J, Elvin J, Vergilio J, Ramkissoon S, Suh J, Severson E, Daniel S, Frampton G, Fabrizio D, Hartmaier R, Albacker L, Ali S, Schrock A, Miller V, et al. Abstract PD8-01: CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas differ in genomic signatures and opportunities for targeted and immunotherapies Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd8-01 |
0.394 |
|
| 2018 |
Ross J, Chung J, Elvin J, Vergilio J, Ramkissoon S, Suh J, Severson E, Daniel S, Frampton G, Fabrizio D, Hartmaier R, Albacker L, Ali S, Schrock A, Miller V, et al. Abstract P2-09-15: NTRK fusions in breast cancer: Clinical, pathologic and genomic findings Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-09-15 |
0.406 |
|
| 2018 |
Necchi A, Bratslavsky G, Corona RJ, Chung J, Millis SZ, Elvin J-, Vergilio J-, Ramkissoon S, Severson E, Daniel S, Killian JK, Ali SM, Schrock AB, Miller VA, Ross JS. Comprehensive genomic profiling (CGP) of chemotherapy-resistant, primary mediastinal nonseminomatous germ cell tumors (PMNSGCT). Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy283.076 |
0.368 |
|
| 2018 |
Pavlick DC, Ramkissoon S, Daniel S, Killian JK, Vergilio J-, Severson E, Frampton GM, Elvin JA, Ross JS. Pan-cancer analysis of ret fusions (FN) and rearrangements (RE) by genomic profiling of 158,360 tumors. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy269.056 |
0.373 |
|
| 2018 |
Liu N, Fisher HAG, Byler T, Jacob J, Chung J, Elvin JA, Vergilio J, Ramkissoon S, Suh J, Severson EA, Daniel S, Ali SM, Schrock AB, Miller VA, Stephens PJ, et al. Pd60-01 Castrate Resistant Tmprss2: Erg Fusion Positive And Tmprss2: Erg Wild Type Refractory Acinar And Neuroendocrine Prostate Cancer Differ In Genomic Signatures And Opportunities For Targeted And Immunotherapies The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2813 |
0.304 |
|
| 2018 |
Jacob JM, Ferry E, Shapiro O, Millis SZ, Chung J, Elvin JA, Virgilio J, Ramkissoon S, Suh J, Severson EA, Liu N, Daniel S, Ali SM, Schrock AB, Miller VA, et al. Mp37-10 Refractory Testicular Pure Seminoma (Ps) And Non-Seminomatous(Ns) Germ Cell Tumors (Gct): A Comprehensive Genomic Profiling (Cgp) Study The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1216 |
0.396 |
|
| 2017 |
Ross JS, Ali SM, Fasan O, Block J, Pal S, Elvin JA, Schrock AB, Suh J, Nozad S, Kim S, Jeong Lee H, Sheehan CE, Jones DM, Vergilio JA, Ramkissoon S, ... Severson E, et al. ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. The Oncologist. PMID 29079636 DOI: 10.1634/Theoncologist.2016-0488 |
0.344 |
|
| 2017 |
Sajed DP, Faquin WC, Carey C, Severson EA, H Afrogheh A, A Johnson C, Blacklow SC, Chau NG, Lin DT, Krane JF, Jo VY, Garcia JJ, Sholl LM, Aster JC. Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and is Associated With Worse Outcome in Adenoid Cystic Carcinoma. The American Journal of Surgical Pathology. PMID 28914715 DOI: 10.1097/Pas.0000000000000945 |
0.329 |
|
| 2017 |
Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Hsu S, Lesser GJ, Stogner-Underwood K, Mott RT, Rush SZ, Stanke JJ, et al. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. The Oncologist. PMID 28912153 DOI: 10.1634/Theoncologist.2017-0242 |
0.352 |
|
| 2017 |
Severson E, Arnett KL, Wang H, Zang C, Taing L, Liu H, Pear WS, Shirley Liu X, Blacklow SC, Aster JC. Genome-wide identification and characterization of Notch transcription complex-binding sequence-paired sites in leukemia cells. Science Signaling. 10. PMID 28465412 DOI: 10.1126/Scisignal.Aag1598 |
0.344 |
|
| 2017 |
Severson EA, Ramkissoon S, Daniel S, Vergilio J, Elvin JA, Suh J, Frampton GM, Ali SM, Miller VA, Ross JS. Association of tumor mutational burden in cutaneous squamous cell carcinoma with genomic alterations in Notch family receptors. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E13031 |
0.395 |
|
| 2017 |
Reddy VP, Elvin JA, Vergilio J, Suh J, Ramkissoon S, Daniel S, Severson EA, Ali SM, Schrock AB, Chung J, Frampton GM, Fabrizio D, Stephens P, Miller VA, Ross JS. BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies. Journal of Clinical Oncology. 35: 9072-9072. DOI: 10.1200/Jco.2017.35.15_Suppl.9072 |
0.391 |
|
| 2017 |
Mayor P, Gornstein E, Morley S, Frampton GM, Heilmann A, Sun J, Chung J, Daniel S, Ramkissoon S, Severson EA, Suh J, Vergilio J, Stephens PJ, Lele SB, Ross JS, et al. BRCA1/2 reversion mutations revealed in breast and gynecologic cancers sequenced during routine clinical care using tissue or liquid biopsy. Journal of Clinical Oncology. 35: 5551-5551. DOI: 10.1200/Jco.2017.35.15_Suppl.5551 |
0.355 |
|
| 2017 |
Elvin JA, He Y, Sun J, Odunsi K, Szender JB, Moore KN, Frampton GM, Vergilio J, Suh J, Ramkissoon S, Severson EA, Daniel S, Lin KK, Hou JY, Gunderson CC, et al. Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC). Journal of Clinical Oncology. 35: 5512-5512. DOI: 10.1200/Jco.2017.35.15_Suppl.5512 |
0.394 |
|
| 2017 |
Daniel S, Gornstein E, Frampton GM, Sun J, Morley S, Heilmann A, Reddy P, Chung J, Suh J, Ramkissoon S, Severson EA, Vergilio J, Stephens PJ, Miller VA, Elvin JA, et al. BRCA1/2 reversion mutations in prostate cancer identified from clinical tissue and liquid biopsy samples. Journal of Clinical Oncology. 35: 5024-5024. DOI: 10.1200/Jco.2017.35.15_Suppl.5024 |
0.372 |
|
| 2017 |
Gornstein E, Frampton GM, Sun J, Morley S, Heilmann A, Chung J, Daniel S, Ramkissoon S, Severson EA, Suh J, Vergilio J, Stephens PJ, Miller VA, Elvin JA, Ross JS. BRCA1/2 reversion mutations in pancreatobiliary cancer identified from patient biopsies. Journal of Clinical Oncology. 35: 4130-4130. DOI: 10.1200/Jco.2017.35.15_Suppl.4130 |
0.353 |
|
| 2017 |
Ross JS, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio J, Ramkissoon S, Severson EA, Daniel S, Fabrizio D, Frampton GM, Miller VA, Stephens PJ. Targeted therapy for HER2 driven colorectal cancer. Journal of Clinical Oncology. 35: 3583-3583. DOI: 10.1200/Jco.2017.35.15_Suppl.3583 |
0.377 |
|
| 2017 |
Gay LM, Fabrizio D, Frampton GM, Connelly CF, Sun J, Daniel S, Elvin JA, Ramkissoon S, Severson EA, Suh J, Vergilio J, Stephens PJ, Ross JS. Mutational burden of tumors with primary site unknown. Journal of Clinical Oncology. 35: 3039-3039. DOI: 10.1200/Jco.2017.35.15_Suppl.3039 |
0.356 |
|
| 2017 |
Connelly CF, Severson EA, Lieu CH, Meyer JE, Stephens P, Frampton GM. The age specific genomic landscape of cancer. Journal of Clinical Oncology. 35: 1568-1568. DOI: 10.1200/Jco.2017.35.15_Suppl.1568 |
0.36 |
|
| 2017 |
Ross JS, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio J, Ramkissoon S, Severson EA, Daniel S, Fabrizio D, Frampton GM, Miller VA, Stephens PJ. Occurrence of ALK fusions in cancers other than non-small cell lung cancer in a wide variety of tumor types and response to anti-ALK targeted therapy. Journal of Clinical Oncology. 35: 11595-11595. DOI: 10.1200/Jco.2017.35.15_Suppl.11595 |
0.341 |
|
| 2017 |
Albanell J, Elvin JA, Ali SM, Schrock AB, Chung J, Vergilio J, Suh J, Ramkissoon S, Severson EA, Daniel S, Miller VA, Stephens PJ, Ross JS. BRAF: An emerging target for triple-negative breast cancer. Journal of Clinical Oncology. 35: 1099-1099. DOI: 10.1200/Jco.2017.35.15_Suppl.1099 |
0.337 |
|
| 2017 |
Ramkissoon S, Albacker L, Severson E, Connelly C, Johnson A, Gay L, Vergilio J, Elvin J, Suh J, Daniel S, Brown C, Covert M, Schrock A, Frampton G, Ali S, et al. PATH-38. COMPREHENSIVE GENOMIC PROFILING OF OLIGODENDROGLIOMAS REFINES TUMOR DIAGNOSES AND IDENTIFIES PATIENTS FOR TARGETED THERAPIES AND IMMUNE CHECKPOINT INHIBITORS Neuro-Oncology. 19: vi179-vi179. DOI: 10.1093/Neuonc/Nox168.728 |
0.353 |
|
| 2017 |
Severson E, Vergilio J, Daniel S, Elvin J, Suh J, Covert M, Brown C, Miller V, Stephens P, Ross J, Ramkissoon S. Path-20. Comprehensive Genomic Profiling Comparing Primary Cns Lymphoma To Systemic Diffuse Large B Cell Lymphoma Reveals Biomarkers Indicating Potential Benefit From Immune Checkpoint Inhibitors Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.711 |
0.306 |
|
| 2017 |
Suh J, Severson E, Hechtman J, Frampton G, Fabrizio D, Sun J, Ali S, Gu P, Klempner S, Miller V, Stephens P, Ross J. 194OHybrid-capture based comprehensive genomic profiling of hepatocellular carcinoma identifies patients who may benefit from targeted therapies and immune checkpoint blockade Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx660.001 |
0.329 |
|
| 2017 |
Ikeda S, Gay L, Pavlick D, Chung J, Ramkissoon S, Daniel S, Elvin J, Severson E, Bivona T, Reckamp K, Klempner S, Ou S, Schrock A, Miller V, Stephens P, et al. Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types Annals of Oncology. 28: x1. DOI: 10.1093/Annonc/Mdx652 |
0.367 |
|
| 2017 |
Ross JS, Borre PV, Almog N, Schrock AB, Chung J, Vergilio J, Suh J, Ramkissoon S, Severson E, Daniel S, Ali SM, Miller VA, Stephens PJ, Elvin JA. 1701OComprehensive Genomic Profiling (CGP) of Thymic Gland Carcinomas Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx391.001 |
0.349 |
|
| 2017 |
Gay L, Pavlick D, Chung J, Ramkissoon S, Daniel S, Elvin J, Severson E, Bivona T, Reckamp K, Klempner S, Ou S, Schrock A, Miller V, Stephens P, Ross J, et al. Genomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types Annals of Oncology. 28: v595. DOI: 10.1093/Annonc/Mdx391 |
0.362 |
|
| 2017 |
Ross JS, Carlson JA, Elvin JA, Vergilio J, Suh J, Ramkissoon S, Severson E, Daniel S, Ali SM, Schrock AB, Fabrizio D, Frampton GM, Miller VA, Stephens PJ, Johnson DB. 1217PDComprehensive genomic profiling (CGP) and tumor mutational burden (TMB) assessment in subtypes of metastatic melanoma Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx377.004 |
0.372 |
|
| 2017 |
Ross JS, Goldberg ME, Albacker LA, Agarwala V, Elvin JA, Vergilio J, Suh J, Ramkissoon S, Severson E, Daniel S, Ali SM, Schrock AB, Frampton GM, Fabrizio D, Miller VA, et al. 1138PDImmune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx376.004 |
0.32 |
|
| 2017 |
Ross JS, Borre PV, Almog N, Schrock AB, Vergilio J, Suh J, Ramkissoon S, Severson E, Daniel S, Ali SM, Miller VA, Stephens PJ, Elvin JA, Bowles D. 433PDComprehensive genomic profiling of metastatic and relapsed thyroid gland carcinomas is associated with tumor type and reveals new routes to targeted therapies Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx368.006 |
0.358 |
|
| 2017 |
Ross JS, Elvin JA, Suh J, Vergilio J, Ramkissoon S, Severson E, Daniel S, Frampton GM, Fabrizio D, Schrock AB, Ali SM, Miller VA, Stephens P, Chung J. 240PDComprehensive genomic profiling of primary and metastatic CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas reveals markers of hormonal therapy resistance and opportunities for targeted therapies Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx365.003 |
0.327 |
|
| 2010 |
Severson EA, Kwon M, Hilgarth RS, Parkos CA, Nusrat A. Glycogen Synthase Kinase 3 (GSK-3) influences epithelial barrier function by regulating occludin, claudin-1 and E-cadherin expression. Biochemical and Biophysical Research Communications. 397: 592-7. PMID 20617560 DOI: 10.1016/J.Bbrc.2010.05.164 |
0.319 |
|
| 2009 |
Severson EA, Parkos CA. Structural determinants of Junctional Adhesion Molecule A (JAM-A) function and mechanisms of intracellular signaling. Current Opinion in Cell Biology. 21: 701-7. PMID 19608396 DOI: 10.1016/J.Ceb.2009.06.005 |
0.319 |
|
| 2009 |
Severson EA, Parkos CA. Mechanisms of outside-in signaling at the tight junction by junctional adhesion molecule A. Annals of the New York Academy of Sciences. 1165: 10-8. PMID 19538282 DOI: 10.1111/J.1749-6632.2009.04034.X |
0.336 |
|
| 2009 |
Severson EA, Lee WY, Capaldo CT, Nusrat A, Parkos CA. Junctional adhesion molecule A interacts with Afadin and PDZ-GEF2 to activate Rap1A, regulate beta1 integrin levels, and enhance cell migration. Molecular Biology of the Cell. 20: 1916-25. PMID 19176753 DOI: 10.1091/Mbc.E08-10-1014 |
0.597 |
|
| 2008 |
Babbin BA, Laukoetter MG, Nava P, Koch S, Lee WY, Capaldo CT, Peatman E, Severson EA, Flower RJ, Perretti M, Parkos CA, Nusrat A. Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. Journal of Immunology (Baltimore, Md. : 1950). 181: 5035-44. PMID 18802107 DOI: 10.4049/Jimmunol.181.7.5035 |
0.547 |
|
| 2008 |
Severson EA, Jiang L, Ivanov AI, Mandell KJ, Nusrat A, Parkos CA. Cis-dimerization mediates function of junctional adhesion molecule A. Molecular Biology of the Cell. 19: 1862-72. PMID 18272784 DOI: 10.1091/Mbc.E07-09-0869 |
0.702 |
|
| 2007 |
Laukoetter MG, Nava P, Lee WY, Severson EA, Capaldo CT, Babbin BA, Williams IR, Koval M, Peatman E, Campbell JA, Dermody TS, Nusrat A, Parkos CA. JAM-A regulates permeability and inflammation in the intestine in vivo. The Journal of Experimental Medicine. 204: 3067-76. PMID 18039951 DOI: 10.1084/Jem.20071416 |
0.573 |
|
| 2007 |
Lee WY, Weber DA, Laur O, Severson EA, McCall I, Jen RP, Chin AC, Wu T, Gernert KM, Gernet KM, Parkos CA. Novel structural determinants on SIRP alpha that mediate binding to CD47. Journal of Immunology (Baltimore, Md. : 1950). 179: 7741-50. PMID 18025220 DOI: 10.4049/Jimmunol.179.11.7741 |
0.534 |
|
| 2007 |
Mandell KJ, Berglin L, Severson EA, Edelhauser HF, Parkos CA. Expression of JAM-A in the human corneal endothelium and retinal pigment epithelium: localization and evidence for role in barrier function. Investigative Ophthalmology & Visual Science. 48: 3928-36. PMID 17724169 DOI: 10.1167/Iovs.06-1536 |
0.692 |
|
| 2007 |
Severson E, Jiang L, Ivanov A, Mandell K, Nusrat A, Parkos CA. Dimerization of Junctional Adhesion Molecule-A (JAM-A) regulates cell migration through prevention of {beta}1 integrin proteosomal degradation. The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A192-A |
0.697 |
|
| Show low-probability matches. |